Continuous Biomanufacturing Patents: Who Leads, Where the Gaps Are 2026
- One filer dominates. The leading assignee holds 12 of the 24 records in scope, with the remaining four ranked assignees trailing well behind — a field with a single strong incumbent rather than a broad competitive set.
- Filing peaked in 2023. 14 records published that year, the high point in a run that only opens up from 2017; the most recent year is necessarily undercounted because publication lags filing by around 18 months.
- Testing and control classes dominate the claims. G01N (material analysis & testing) touches 91.7% of the 24 records and C12M (bioreactors & enzyme apparatus) touches 70.8% — separation processes under B01D appear in just 12.5%.
Top-5 share is the combined record count of the five largest assignees divided by all 24 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Continuous biomanufacturing replaces the batch tanks and hold steps of conventional biologics production with an uninterrupted process flow, which shifts the engineering burden onto in-line measurement, control loops and material handling rather than end-of-batch release testing. The 24 records in this scope combine claims on process analytical instruments, bioreactor apparatus, mixing and separation hardware, and the control logic that ties them together — a search built around continuous biomanufacturing terms paired with process temperature, tool geometry, material feed, dimensional tolerance, quality control and delivery vehicle language.
The dataset is small and concentrated: five ranked assignees account for every one of the 24 records, and one of them alone accounts for half. That combination — a narrow applicant base with a dominant filer inside it — is itself the finding, more informative here than any growth curve the trend line could offer.
Filing trend and technology composition
Two views of the same 24 records: how filings have moved year over year, and which IPC subclasses carry the claims.
Filing trend, 2017–2026
Filings rose from zero in 2017 to a peak of 14 in 2023 before the most recent, partial year. With fewer than four complete years of data once the roughly 18-month publication lag is accounted for, a growth rate cannot be stated reliably from this trend alone.
IPC subclass composition
G01N (material analysis & testing) and C12M (bioreactors & enzyme apparatus) between them cover the large majority of the 24 records, confirming that measurement and vessel/apparatus claims are where the filing activity concentrates. B01F and G05D each sit at 41.7%, and B01D separation processes trail at 12.5% — since a record can carry several IPC classes, these shares add up to more than 100% of the record total.
Shares are the percentage of the 24 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Continuous Biomanufacturing Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about continuous biomanufacturing patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaA representative claim in this space
Modular process analytical technology testing apparatus
The invention provides a modular apparatus comprising at least one process analytical instrument and a controller adapted for fluid communication with a unit operation of a pharmaceutical or biopharmaceutical manufacturing system, systems comprising the modular apparatus, and related compositions and methods. The modular apparatuses described here and associated digital architecture provide a universal solution to fully integrate any pharmaceutical or biopharmaceutical manufacturing process using a wide range of process analytic tools.Filed by Arranta Bio Holdings, published 2025-09-18 — one of the most recent records in scope.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2024076757A1 | Product formulation in biological manufacturing | 1 |
Citation counts inside a searched corpus favour older filings; treat the ranking as a signal of influence rather than of current technical importance.
Publication numbers are shown where the record carries one (1 of 1 rows); clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say
Three read-outs from the same 24-record dataset, each pointing at a different decision a filer or licensor would need to make.
A closed applicant set, not an open field
Every one of the 24 records in scope traces to one of just five ranked assignees, and the leader alone holds 12. New entrants are not filing around an established crowd here — they would be filing into a field with almost no independent voices at all.
Measurement and vessel claims carry the field
Material analysis and testing (G01N) and bioreactor apparatus (C12M) between them appear in the large majority of records. Mixing (B01F) and non-electric control (G05D) sit at just over two-fifths each, and separation processes (B01D) are comparatively rare at 12.5%.
Activity is recent and still settling
The run starts from zero in 2017 and rises to its observed peak in 2023 before the partial final year. Because publication lags filing by roughly 18 months, the most recent year understates true filing activity and should not be read as a decline.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to continuous biomanufacturing patent landscape, with the prior art for and against each one.
Who is filing, and where the openings sit
The ranked assignee list is short and dominated by one filer, which changes how a newcomer should think about clearing space here.
One filer holds half the dataset
The leading assignee's count of 12 out of 24 records means any freedom-to-operate review in this space starts with a single portfolio, not a diffuse landscape. Recent-year momentum for this filer is flat at zero for the latest year, consistent with the publication-lag effect across the whole dataset rather than a pullback.
The remaining four assignees are thin
Below the leader, the ranked list drops quickly — the fifth-place assignee holds just a single record. That gap is a normal signature of a technical niche still forming around one strong first mover, rather than an established multi-player race.
Filings spread across three major offices evenly
Europe, the United States and the WIPO PCT route each carry 4 records, with Israel and India at 2 each and Australia at 1. That spread suggests applicants are pursuing multi-jurisdiction protection rather than concentrating on a single home market.
| Assignee | Recent year | YoY |
|---|---|---|
| Genzyme Corporation | 0 | -100% |
| Sartorius Stedim Biotech | 0 | — |
| Sanofi | 0 | — |
| ARRANTA BIO HOLDINGS LLC | 0 | -100% |
| Rutgers University | 0 | — |
Where to take this analysis
The dataset points to a concentrated field with one dominant filer and several lightly claimed branches. The next steps depend on whether the goal is clearance, licensing or new filing.
Run a freedom-to-operate check against the leading portfolio
With one assignee holding half the records in scope, any product or process work in continuous biomanufacturing should start by mapping claims against that single portfolio before looking at the rest of the field.
Explore claims in EurekaTest the under-claimed branches for a first-mover filing
Separation processes and dimensional tolerance sensing show the lightest claim density in this scope. A claim drafted around in-line separation control, for instance, would face comparatively little cited prior art here.
Draft claim scope in EurekaTrack the next publication window
Because publication lags filing by roughly 18 months, the true 2025-2026 filing count will only become visible over the next few quarters. Revisit the trend once that lag closes.
Set a monitoring alert in EurekaCommon questions about this landscape
Within this 24-record dataset, patent activity is concentrated among just five ranked assignees, and one of them holds 12 of the 24 records on its own. The remaining four assignees hold far smaller counts, down to a single record for the fifth-ranked filer. That pattern means the field currently reads as one strong incumbent portfolio surrounded by a thin tail of smaller filers, rather than a broad competitive set.
The claims cluster heavily around material analysis and testing (IPC class G01N, present in 91.7% of the 24 records) and bioreactor or enzyme apparatus (C12M, 70.8%). Mixing and stirring equipment (B01F) and control of non-electric variables (G05D) each appear in around two-fifths of records, while separation processes such as filtration (B01D) are comparatively rare at 12.5%. Because a single record can carry multiple IPC classes, these percentages add up to more than the total record count, which is expected.
Filing activity rose from zero in 2017 to a peak of 14 records in 2023, but there are fewer than four complete filing years once the roughly 18-month publication lag is factored in, so a reliable growth rate cannot be calculated from this data. The most recent year always looks lower than it will eventually turn out to be once pending applications publish. Treat the 2023 peak as the clearest signal currently available rather than assuming a downward trend afterward.
The IPC composition shows separation processes (B01D, filtration and related techniques) present in only 12.5% of the 24 records, the lightest coverage of any class tracked here, alongside comparatively thinner claim density around dimensional tolerance sensing and material feed calibration for continuous flow. These are reasonable areas to investigate for a first claim, since they sit adjacent to the heavily claimed testing and bioreactor classes without being crowded themselves. Any filing strategy here should still run a targeted prior-art search rather than relying on the IPC share alone.
US20250290910A1, filed by Arranta Bio Holdings and published in September 2025, claims a modular process analytical technology apparatus — an instrument-plus-controller unit designed to sit in fluid communication with a manufacturing unit operation and integrate with a wider digital architecture. It matters because it represents one of the more recent filings in a dataset where a single company already holds half the ranked records, so its claim scope is worth checking closely by anyone designing in-line PAT tooling for continuous processes. The abstract's emphasis on a 'universal solution' for integrating a wide range of process analytic tools suggests the claims may be drafted broadly around modularity and controller-instrument fluid communication.
Research Continuous Biomanufacturing Patent Landscape in depth with Eureka
Go past this page: query the whole continuous biomanufacturing patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.